MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2022
GAITHERSBURG, MD, May 10, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended March 31, 2022.
A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400
|
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden
|
+44 (0)20 7886 2500 |
| UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709 5700
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
